JX7.F EMBECTA CORP. DL-01
- Market cap
- EUR 324M
- P/E
- 4.5x
- P/B
- -
- ROE
- -
- Dividend yield
- 0.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is JX7.F undervalued?
Graham numberThe Graham number of EMBECTA CORP. DL-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EMBECTA CORP. DL-01 fundamental analysis
No fundamental analysis for EMBECTA CORP. DL-01 yet.
EMBECTA CORP. DL-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EMBECTA CORP. DL-01
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded …
Full company profileEMBECTA CORP. DL-01 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EMBECTA CORP. DL-01 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 1.13B | 1.12B | 1.12B | 1.08B | 1.01B |
| Gross Profit | 775M | 750M | 735M | 677M | 590M |
| Operating Income | 369M | 224M | 285M | 296M | 245M |
| EBITDA | 335M | 245M | 193M | 284M | 274M |
| Net Income | 224M | 70.4M | 78.3M | 95.4M | 81.5M |
| EPS | 3.92 | 1.23 | 1.36 | 1.63 | 1.44 |
| Balance Sheet | |||||
| Total Assets | 1.09B | 1.21B | 1.29B | 1.09B | 1.27B |
| Total Liabilities | 1.98B | 2.04B | 2.02B | 1.74B | 1.88B |
| Shareholders' Equity | -891M | -822M | -739M | -651M | -613M |
| Cash & Short-term Investments | 331M | 326M | 268M | 226M | 215M |
| Cash Flow | |||||
| Operating Cash Flow | 412M | 67.7M | 35.7M | 192M | 120M |
| Capital Expenditure | 24.0M | 26.5M | 15.8M | 9.30M | 2.93M |
| Free Cash Flow | 388M | 41.2M | 19.9M | 182M | 117M |
| Ratios | |||||
| ROA | 20.6% | 5.8% | 6.1% | 8.7% | 6.4% |
| Net Profit Margin | 19.8% | 6.3% | 7.0% | 8.8% | 8.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
EMBECTA CORP. DL-01 dividends
- Dividend yield
- 0.61%
- Forward dividend
- 0.03 EUR
- Payout ratio
- 36.7%
- Ex-dividend date
- Aug 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 35.0M | 0.60 | 36.7% |
| 2024 | USD 34.5M | 0.60 | 44.1% |
| 2023 | USD 34.4M | 0.60 | 48.9% |
| 2022 | USD 8.60M | 0.15 | 3.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns EMBECTA CORP. DL-01
- Insiders 2.01%
- Institutions 92.57%
- Public & others 5.43%
- Shares outstanding 56.7M
- Free float 54.8M
EMBECTA CORP. DL-01 company profile
- Company name
- EMBECTA CORP. DL-01
- Ticker
- JX7.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,850
- Fiscal year end
- September
- Address
- 300 Kimball Drive, Parsippany, NJ, United States, 07054
- Phone
- 862 401 0000
- Website
- embecta.com
About EMBECTA CORP. DL-01
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
EMBECTA CORP. DL-01 management
10- Mr. Devdatt Kurdikar Ph.D.President, CEO & Chairman · born 1969
- Mr. Jacob P. ElguiczeSenior VP & CFO · born 1973
- Mr. Jeffrey Z. MannSenior VP, General Counsel, Head of Business Development & Corporate Secretary · born 1972
- Ms. Jean M. CasnerSenior VP & Chief Human Resources Officer · born 1958
- Mr. Shaun CurtisSenior Vice President of Global Manufacturing & Supply Chain · born 1970
- Mr. Anthony M. RothVP, Chief Accounting Officer & Corporate Controller · born 1973
- Mr. Pravesh KhandelwalVP & Head of Investor Relations
- Ms. Ginny BlockiSenior Vice President of Strategy
- Mr. Tom BlountSenior VP & President of North America · born 1974
- Mr. Slobodan RadumiloSenior VP & President of International · born 1971